July 24, 2026 03:19 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'No assurances, sack Dharmendra Pradhan': CJP fires back at PM Modi over NEET row | 'Don't insult students': Rahul Gandhi tears into PM Modi's midnight NEET video, demands Dharmendra Pradhan's exit | Trump slaps fresh tariffs on India, China and 58 others over forced labour concerns | Sonam Wangchuk ends 26-day hunger strike after 'long negotiations', urges CJP protesters to maintain peace | PM Modi promises fresh steps on paper leaks in late night video | NEET protest: Centre invites CJP for talks; protesters stick to Jantar Mantar or neutral venue demand | Khalistani terrorist Pannun announces $1 million support for CJP protests, calls for 'balkanisation of India' | 'We'll put drugs in your bag': Mumbai cop suspended after viral threat to NEET protesters | 'Fulfill the demands first': CJP hits back at PM Modi's message for youth | Delhi cop seen slapping woman protester removed from Jantar Mantar after viral outrage
COVID-19
Image: PIB

Momentous feat: PM Modi after world's first DNA based anti-COVID-19 vaccine ZyCov-D gets nod

| @indiablooms | Aug 21, 2021, at 04:36 pm

New Delhi/IBNS: Prime Minister Narendra Modi has lauded the scientists after the world's first DNA based anti-COVID-19 vaccine, ZyCov-D, got approval for an emergency use in India.

The Prime Minister tweeted, "India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."

Zydus Cadila Friday received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.

Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.

This three-dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance.

The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.